Sarah Condella - 23 Dec 2025 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
EVP, Human Resources
Signature
/s/ Sarah Condella by Mark Busch, attorney-in- fact
Issuer symbol
EXAS
Transactions as of
23 Dec 2025
Net transactions value
-$4,270,127
Form type
4
Filing time
30 Dec 2025, 16:30:09 UTC
Previous filing
04 Mar 2025
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Condella Sarah EVP, Human Resources C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON /s/ Sarah Condella by Mark Busch, attorney-in- fact 30 Dec 2025 0001839989

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Options Exercise $0 +3,955 +4.8% $0.000000 85,801 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $189,283 -1,859 -2.2% $101.82 83,942 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +7,560 +9% $0.000000 91,502 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $361,868 -3,554 -3.9% $101.82 87,948 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +11,876 +14% $0.000000 99,824 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $568,359 -5,582 -5.6% $101.82 94,242 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +23,817 +25% $0.000000 118,059 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $1,139,773 -11,194 -9.5% $101.82 106,865 23 Dec 2025 Direct F2
transaction EXAS Common Stock Award $0 +34,018 +32% $0.000000 140,883 23 Dec 2025 Direct F3
transaction EXAS Common Stock Tax liability $1,628,000 -15,989 -11% $101.82 124,894 23 Dec 2025 Direct F4
transaction EXAS Common Stock Award $0 +8,000 +6.4% $0.000000 132,894 23 Dec 2025 Direct F5
transaction EXAS Common Stock Tax liability $382,843 -3,760 -2.8% $101.82 129,134 23 Dec 2025 Direct F4, F6
holding EXAS Common Stock 6,100 23 Dec 2025 Held in 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXAS Restricted Stock Units Options Exercise $0 -3,955 -100% $0.000000 0 23 Dec 2025 Common Stock 3,955 Direct F7, F8
transaction EXAS Restricted Stock Units Options Exercise $0 -7,560 -100% $0.000000 0 23 Dec 2025 Common Stock 7,560 Direct F7, F9
transaction EXAS Restricted Stock Units Options Exercise $0 -11,876 -100% $0.000000 0 23 Dec 2025 Common Stock 11,876 Direct F7, F10
transaction EXAS Restricted Stock Units Options Exercise $0 -23,817 -100% $0.000000 0 23 Dec 2025 Common Stock 23,817 Direct F7, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units.
F3 Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation").
F4 Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units.
F5 Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F6 In addition to the shares of Common Stock reported on this Form 4, which total 135,234 shares, Ms. Condella also holds, in the aggregate, an additional 51,919 vested and unvested options to purchase shares of Common Stock.
F7 Each restricted stock unit represents a contingent right to receive one share of common stock.
F8 This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F9 This award was scheduled to vest in two equal installments on February 27, 2026 and February 26, 2027, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F10 This award was scheduled to vest in three equal installments on February 27, 2026, February 26, 2027, and February 29, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F11 This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.